154 related articles for article (PubMed ID: 23585918)
1. Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.
Harvey JH; Long DH; England PM; Whistler JL
ACS Med Chem Lett; 2012 Aug; 3(8):640-644. PubMed ID: 23585918
[TBL] [Abstract][Full Text] [Related]
2. Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism.
Milan-Lobo L; Enquist J; van Rijn RM; Whistler JL
PLoS One; 2013; 8(3):e58362. PubMed ID: 23554887
[TBL] [Abstract][Full Text] [Related]
3. Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.
Milan-Lobo L; Whistler JL
J Pharmacol Exp Ther; 2011 Jun; 337(3):868-75. PubMed ID: 21422164
[TBL] [Abstract][Full Text] [Related]
4. Heteromer Induction: An Approach to Unique Pharmacology?
Portoghese PS; Akgün E; Lunzer MM
ACS Chem Neurosci; 2017 Mar; 8(3):426-428. PubMed ID: 28139906
[TBL] [Abstract][Full Text] [Related]
5. Evidence and Function Relevance of Native DOR-MOR Heteromers.
Cahill CM; Ong E
Handb Exp Pharmacol; 2018; 247():115-127. PubMed ID: 29633181
[TBL] [Abstract][Full Text] [Related]
6. Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse Colon.
DiCello JJ; Carbone SE; Saito A; Rajasekhar P; Ceredig RA; Pham V; Valant C; Christopoulos A; Veldhuis NA; Canals M; Massotte D; Poole DP
Cell Mol Gastroenterol Hepatol; 2020; 9(3):465-483. PubMed ID: 31759144
[TBL] [Abstract][Full Text] [Related]
7. Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain.
Bushlin I; Gupta A; Stockton SD; Miller LK; Devi LA
PLoS One; 2012; 7(12):e49789. PubMed ID: 23272051
[TBL] [Abstract][Full Text] [Related]
8. Functional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area.
Moreno E; Quiroz C; Rea W; Cai NS; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; Ferré S
J Neurosci; 2017 Feb; 37(5):1176-1186. PubMed ID: 28007761
[TBL] [Abstract][Full Text] [Related]
9. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
[TBL] [Abstract][Full Text] [Related]
10. Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.
Kabli N; Martin N; Fan T; Nguyen T; Hasbi A; Balboni G; O'Dowd BF; George SR
Br J Pharmacol; 2010 Nov; 161(5):1122-36. PubMed ID: 20977461
[TBL] [Abstract][Full Text] [Related]
11. Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.
Anand JP; Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
Chem Biol Drug Des; 2012 Nov; 80(5):763-70. PubMed ID: 22882801
[TBL] [Abstract][Full Text] [Related]
12. Interactions between cannabinoid and opioid receptors in a mouse model of diabetic neuropathy.
Toniolo EF; Gupta A; Franciosi AC; Gomes I; Devi LA; Dale CS
Pain; 2022 Jul; 163(7):1414-1423. PubMed ID: 34724682
[TBL] [Abstract][Full Text] [Related]
13. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
14. Molecular Perspectives for mu/delta Opioid Receptor Heteromers as Distinct, Functional Receptors.
Ong EW; Cahill CM
Cells; 2014 Mar; 3(1):152-79. PubMed ID: 24709907
[TBL] [Abstract][Full Text] [Related]
15. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation.
Ji RR; Zhang Q; Law PY; Low HH; Elde R; Hökfelt T
J Neurosci; 1995 Dec; 15(12):8156-66. PubMed ID: 8613750
[TBL] [Abstract][Full Text] [Related]
16. Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain.
Sierra S; Gupta A; Gomes I; Fowkes M; Ram A; Bobeck EN; Devi LA
ACS Pharmacol Transl Sci; 2019 Aug; 2(4):219-229. PubMed ID: 31565698
[TBL] [Abstract][Full Text] [Related]
17. Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.
Margolis EB; Fujita W; Devi LA; Fields HL
Neuropharmacology; 2017 Sep; 123():420-432. PubMed ID: 28645621
[TBL] [Abstract][Full Text] [Related]
18. Mu and delta opioid receptor knockout mice show increased colonic sensitivity.
Reiss D; Ceredig RA; Secher T; Boué J; Barreau F; Dietrich G; Gavériaux-Ruff C
Eur J Pain; 2017 Apr; 21(4):623-634. PubMed ID: 27748566
[TBL] [Abstract][Full Text] [Related]
19. Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.
Przydzial MJ; Pogozheva ID; Ho JC; Bosse KE; Sawyer E; Traynor JR; Mosberg HI
J Pept Res; 2005 Nov; 66(5):255-62. PubMed ID: 16218993
[TBL] [Abstract][Full Text] [Related]
20. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment.
Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G
Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
